No REMS Required: Aduhelm’s ARIA Risks, MRI Guidance Conveyed In Labeling, Voluntary Communications
Executive Summary
US FDA cites expected sophistication of specialty prescribers in explaining why a Risk Evaluation and Mitigation Strategy was not needed for the Alzheimer’s drug, even though Biogen had submitted one.